Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LELegend Biotech Corporation logo

Legend Biotech Corporation (LEGN)

NASDAQ · Currency in USD
$19.27 ▲ +0.37 (+1.96%)
At close: Oct 23, 4:00 PM ET. Market closed.
$19.25 ▼ -0.02 (-0.10%)
After hours: Oct 23, 7:37 PM ET

Summary

Previous Close
$18.90
Open
$18.87
Day's Range
$18.44 – $19.30
52 Week Range
$16.24 – $37.50
Volume
979,530
Avg. Volume
2,349,080
Market Cap
$3.56B
Beta (5Y Monthly)
0.40
PE Ratio (TTM)
--
EPS (TTM)
-$0.49
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$61.00

Profile: Legend Biotech Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
3,200
CEO
Alan S. Bash

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate $0.01 · Revenue est. $361.46M
DateEst.Actual
Aug 11, 2026$0.12$0.09Miss
May 12, 2026-$0.02-$0.15Miss
Mar 10, 2026-$0.17-$0.08Beat
Nov 12, 2025-$0.13-$0.11Beat
Aug 11, 2025-$0.11-$0.34Miss
May 13, 2025-$0.23-$0.07Beat

Analyst view

Consensus price target
$61.00 ▲ +216.6%
Range $40.00 – $78.00
Rating: Buy
Buy 70% · Hold 30% · Sell 0%

Get free alerts on LEGN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.